Literature DB >> 15878807

Activating transcription factor 2 expression in the adult human brain: association with both neurodegeneration and neurogenesis.

A G Pearson1, M A Curtis, H J Waldvogel, R L M Faull, M Dragunow.   

Abstract

Activating transcription factor 2 (ATF2) is a member of the activator protein-1 family of transcription factors, which includes c-Jun and c-Fos. ATF2 is highly expressed in the mammalian brain although little is known about its function in nerve cells. Knockout mouse studies show that this transcription factor plays a role in neuronal migration during development but over-expression of ATF2 in neuronal-like cell culture promotes nerve cell death. Using immunohistochemical techniques we demonstrate ATF2 expression in the normal human brain is neuronal, is found throughout the cerebral cortex and is particularly high in the granule cells of the hippocampus, in the brain stem, in the pigmented cells of the substantia nigra and locus coeruleus, and in the granule and molecular cell layers of the cerebellum. In contrast to normal cases, ATF2 expression is down-regulated in the hippocampus, substantia nigra pars compacta and caudate nucleus of the neurological diseases Alzheimer's, Parkinson's and Huntington's, respectively. Paradoxically, an increase in ATF2 expression was found in the subependymal layer of Huntington's disease cases, compared with normal brains; a region reported to contain increased numbers of proliferating progenitor cells in Huntington's disease. We propose ATF2 plays a role in neuronal viability in the normal brain, which is compromised in susceptible regions of neurological diseases leading to its down-regulation. In contrast, the increased expression of ATF2 in the subependymal layer of Huntington's disease suggests a role for ATF2 in some aspect of neurogenesis in the diseased brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878807     DOI: 10.1016/j.neuroscience.2005.02.029

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  19 in total

Review 1.  Location, location, location: altered transcription factor trafficking in neurodegeneration.

Authors:  Charleen T Chu; Edward D Plowey; Ying Wang; Vivek Patel; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2007-10       Impact factor: 3.685

Review 2.  ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease.

Authors:  Gregory Watson; Ze'ev A Ronai; Eric Lau
Journal:  Pharmacol Res       Date:  2017-02-15       Impact factor: 7.658

3.  ATF2 - at the crossroad of nuclear and cytosolic functions.

Authors:  Eric Lau; Ze'ev A Ronai
Journal:  J Cell Sci       Date:  2012-06-08       Impact factor: 5.285

4.  Molecular signatures of selection on the human GLI3 associated central nervous system specific enhancers.

Authors:  Irfan Hussain; Rabail Zehra Raza; Shahid Ali; Muhammad Abrar; Amir Ali Abbasi
Journal:  Dev Genes Evol       Date:  2021-03-02       Impact factor: 0.900

5.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

6.  A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.

Authors:  Alexander Kurz; Kay L Double; Isabel Lastres-Becker; Alessandro Tozzi; Michela Tantucci; Vanessa Bockhart; Michael Bonin; Moisés García-Arencibia; Silke Nuber; Falk Schlaudraff; Birgit Liss; Javier Fernández-Ruiz; Manfred Gerlach; Ullrich Wüllner; Hartmut Lüddens; Paolo Calabresi; Georg Auburger; Suzana Gispert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

7.  Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.

Authors:  Anna Sergeevna Sowa; Elodie Martin; Inês Morgado Martins; Jana Schmidt; Reinhard Depping; Jonasz Jeremiasz Weber; Franziska Rother; Enno Hartmann; Michael Bader; Olaf Riess; Hervé Tricoire; Thorsten Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-23       Impact factor: 11.205

8.  Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide.

Authors:  Taurean Brown; Taylor McElroy; Pilar Simmons; Huddoy Walters; Fabio Ntagwabira; Jing Wang; Stephanie D Byrum; Antiño R Allen
Journal:  Brain Res       Date:  2021-03-08       Impact factor: 3.610

9.  Genotoxicants target distinct molecular networks in neonatal neurons.

Authors:  Glen E Kisby; Antoinette Olivas; Melissa Standley; Xinfang Lu; Patrick Pattee; Jean O'Malley; Xiaorong Li; Juan Muniz; Srinavasa R Nagalla
Journal:  Environ Health Perspect       Date:  2006-11       Impact factor: 9.031

Review 10.  The regulatory role of activating transcription factor 2 in inflammation.

Authors:  Tao Yu; Yong Jun Li; Ai Hong Bian; Hui Bin Zuo; Ti Wen Zhu; Sheng Xiang Ji; Fanming Kong; De Qing Yin; Chuan Bao Wang; Zi Fu Wang; Hong Qun Wang; Yanyan Yang; Byong Chul Yoo; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2014-06-23       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.